SCHEMBL10084154

SCHEMBL10084154

Cc1nncc2cccnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
MAPT P10636 5/20 0.46
CCR1 P32246 4/20 0.46
CCR8 P51685 4/20 0.46
LMNA P02545 4/20 0.46
CCR5 P51681 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
HSP90AA1 P07900 2/20 0.46
MMP2 P08253 2/20 0.46
TSHR P16473 2/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GMNN O75496 1/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MMP9 P14780 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
MMP8 P22894 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30557034 0.76 MMP2 (0.48) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL26123221 0.76 CCR1 (0.46) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL3234181 0.76 MMP2 (0.48) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL30556846 0.76 CCR1 (0.46) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL29559557 0.76 CCR1 (0.46) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL17497064 0.76 CCR1 (0.46) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL19249169 0.76 PDE4A (0.43) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL10077957 0.76 CCR1 (0.42) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL9375947 0.75 CCR1 (0.42) KDM4EMAPTCCR1CCR8LMNA
SCHEMBL17319744 0.73 L3MBTL1 (0.48) KDM4EMAPTCCR1CCR8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023180189-A1 MPRO TARGETING ANTIVIRAL COMPOUNDS EXSCIENTIA AI LIMITED (GB) 2023-09-28 WO disclosed
US-11245078-B2 Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-02-08 US disclosed
US-20200075868-A1 Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity UNIV ARIZONA STATE (US) 2020-03-05 US disclosed
US-10211411-B2 Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2019-02-19 US disclosed
US-20170077420-A1 Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-03-16 US disclosed
US-20160311871-A1 RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-10-27 US disclosed
EP-3064582-A1 RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN Taiho Pharmaceutical Co., Ltd. (JP) 2016-09-07 EP disclosed
WO-2015050235-A1 RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN 大鵬薬品工業株式会社 2015-04-09 WO disclosed
US-8575166-B2 Phthalazine-containing antidiabetic compounds MERCK SHARP & DOHME CORP. (US) 2013-11-05 US disclosed
US-20120004234-A1 PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS SCHERING CORPORATION (US) 2012-01-05 US disclosed
WO-2010091176-A1 PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS SCHERING CORPORATION (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004234-A1 PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS GPR119, FFAR2, FFAR1 KDM4E 2154/4885MAPT 3132/4885CCR1 3731/4885
US-20170077420-A1 Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity HSPA9, CASP9, PARP9 KDM4E 1943/4885MAPT 1400/4885CCR1 4378/4885
US-20160311871-A1 RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN HSP90AB1, HSP90AA1, HSP90AB2P KDM4E 2950/4885MAPT 1891/4885CCR1 4072/4885
US-11245078-B2 Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity HSPA9, CASP9, PARP9 KDM4E 1943/4885MAPT 1400/4885CCR1 4378/4885
US-20200075868-A1 Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity HSPA9, CASP9, PARP9 KDM4E 1943/4885MAPT 1400/4885CCR1 4378/4885
US-10211411-B2 Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity HSPA9, CASP9, PARP9 KDM4E 1902/4885MAPT 1403/4885CCR1 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.